Results 151 to 160 of about 108,380,509 (205)

A brain-first framework for perimenopause management: the case for non-invasive neuromodulation. [PDF]

Front Glob Womens Health
Radytė E, Karvelyte I.
europepmc   +1 more source

Safety and tolerability of elinzanetant: a pooled analysis from four randomized clinical trials. [PDF]

EClinicalMedicine
Pinkerton JV, Francuski M, Nappi RE, Simon JA, Lu C, Djordjevic S, Seitz C, Panay N.   +7 more
europepmc   +1 more source

Detection of an Antagonist Bound to the Neurokinin a Receptor in Styrene-Maleic Acid Lipid Particles by ¹⁹F Ultrafast Magic-Angle Spinning Nuclear Magnetic Resonance Spectroscopy. [PDF]

Chembiochem
Seidl S, Patra AP, Li C, Becker-Baldus J, Kaiser S, Reinhart C, Glaubitz C.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Safety of neurokinin-1 receptor antagonists

Expert Opinion on Drug Safety, 2013
The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many pathological processes. NK-1 receptor antagonists have many promising therapeutic indications. However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodrug, fosaprepitant.
Miguel, Muñoz, Rafael, Coveñas
openaire   +2 more sources

A selective and extremely potent antagonist of the neurokinin-1 receptor

Brain Research, 1992
Sendide [Tyr6,D-Phe7,D-His9]-substance P(6-11) has been examined by measurements of ligand binding to crude membrane fractions and by functional tests on the spinally mediated behavioral response. Sendide potently displaced [3H]-labeled substance P (SP) binding to mouse spinal cord membranes in a competitive manner.
T, Sakurada, Y, Manome, K, Tan-No, S, Sakurada, K, Kisara, M, Ohba, L, Terenius   +6 more
openaire   +3 more sources

Neurokinin-1 receptor antagonists: a comprehensive patent survey

Expert Opinion on Therapeutic Patents, 2010
Substance P is involved in mediating a number of biological effects such as emesis, pain, inflammation, bronchoconstriction, antitumor activity, and regulation of gastrointestinal and CNS function by binding to the neurokinin-1 (NK1) receptor. Antagonists of this receptor have the potential to be useful in the treatment of various disease conditions ...
Shih-Chung, Huang, Vijaya L, Korlipara
openaire   +2 more sources

Neurokinin-1 Receptor Antagonists as Anticancer Drugs

Letters in Drug Design & Discovery, 2019
Background::Human tumor cells lines and tumor samples overexpress the neurokinin-1 receptor (NK-1R). Substance P (SP), after binding to NK-1Rs, induces tumor cell proliferation, an antiapoptotic effect and promotes angiogenesis and the migration of cancer cells for invasion and metastasis.Methods: :In contrast, NK-1R antagonists block the previous ...
Muñoz Sáez, Miguel, Coveñas, Rafael
openaire   +2 more sources

Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach

Anti-Cancer Agents in Medicinal Chemistry, 2019
Background:In adults, the most lethal and frequent primary brain tumor is glioblastoma. Despite multimodal aggressive therapies, the median survival time after diagnosis is around 15 months. In part, this is due to the blood-brain barrier that restricts common treatments (e.g., chemotherapy). Unfortunately, glioma recurs in 90% of patients.
Miguel, Muñoz, Rafael, Coveñas
openaire   +2 more sources

Neurokinin-1 receptor antagonist SR140333

NeuroReport, 1997
Substance P (SP) has been implicated in immune responses and could increase glutamate release, and inflammatory reactions are known to be able to potentiate ischemic damage. We have previously found that SP was over-expressed in cerebral ischemia and speculated that SP may play a role in exacerbating ischemic damage.
Z, Yu, G, Cheng, X, Huang, K, Li, X, Cao
openaire   +2 more sources